Polivy (polatuzumab vedotin) is an antibody pharmaceutical. Polatuzumab vedotin was first approved as Polivy on 2019-06-10. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat b-cell lymphoma. The pharmaceutical is active against B-cell antigen receptor complex-associated protein beta chain.
|Common Name||Polatuzumab vedotin|
|Indication||b-cell lymphoma, large b-cell lymphoma diffuse|
|Drug Class||Synthetic analogs of the dolastatin series; monoclonal antibodies: humanized, tumors as target|